MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK.
Youjin NaAshley HallKwangmin ChoiLiang HuJonathan RoseRobert A CooverAdam MillerRobert F HenniganEva DombiMi-Ok KimSubbaya SubramanianNancy RatnerJianqiang WuPublished in: Oncogene (2020)
MicroRNAs (miRs) are small non-coding RNAs that can have large impacts on oncogenic pathways. Possible functions of dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs). In PNFs, Schwann cells (SCs) have biallelic NF1 mutations necessary for tumorigenesis. We analyzed a miR microarray comparing with normal and PNF SCs and identified differences in miR expression, and we validated in mouse PNFs versus normal mouse SCs by qRT-PCR. Among these, miR-155 was a top overexpressed miR, and its expression was regulated by RAS/MAPK signaling. Overexpression of miR-155 increased mature Nf1-/- mouse SC proliferation. In SC precursors, which model tumor-initiating cells, pharmacological and genetic inhibition of miR-155 decreased PNF-derived sphere numbers in vitro, and we identified Maf as a miR-155 target. In vivo, global deletion of miR-155 significantly decreased tumor number and volume, increasing mouse survival. Fluorescent nanoparticles entered PNFs, suggesting that an anti-miR might have therapeutic potential. However, treatment of established PNFs using anti-miR-155 peptide nucleic acid-loaded nanoparticles marginally decreased tumor numbers and did not reduce tumor growth. These results suggest that miR-155 plays a functional role in PNF growth and/or SC proliferation, and that targeting neurofibroma miRs is feasible, and might provide novel therapeutic opportunities.
Keyphrases
- cell proliferation
- long non coding rna
- long noncoding rna
- signaling pathway
- poor prognosis
- pi k akt
- induced apoptosis
- oxidative stress
- drug delivery
- cell cycle arrest
- immune response
- intellectual disability
- toll like receptor
- genome wide
- transcription factor
- endoplasmic reticulum stress
- cell death
- combination therapy
- fluorescent probe